These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 20713862)

  • 1. Parenchymal versus nonparenchymal target lesion response in clinical trials for metastatic medullary thyroid cancer.
    Machens A; Dralle H
    J Clin Oncol; 2010 Oct; 28(28):e534: author reply e535-6. PubMed ID: 20713862
    [No Abstract]   [Full Text] [Related]  

  • 2. Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer.
    Lam ET; Ringel MD; Kloos RT; Prior TW; Knopp MV; Liang J; Sammet S; Hall NC; Wakely PE; Vasko VV; Saji M; Snyder PJ; Wei L; Arbogast D; Collamore M; Wright JJ; Moley JF; Villalona-Calero MA; Shah MH
    J Clin Oncol; 2010 May; 28(14):2323-30. PubMed ID: 20368568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Harvesting the low-hanging fruit: kinase inhibitors for therapy of advanced medullary and nonmedullary thyroid cancer.
    Fagin JA; Tuttle RM; Pfister DG
    J Clin Endocrinol Metab; 2010 Jun; 95(6):2621-4. PubMed ID: 20525911
    [No Abstract]   [Full Text] [Related]  

  • 4. Medullary thyroid cancer: targeting the RET kinase pathway with sorafenib/tipifarnib.
    Hong D; Ye L; Gagel R; Chintala L; El Naggar AK; Wright J; Kurzrock R
    Mol Cancer Ther; 2008 May; 7(5):1001-6. PubMed ID: 18445656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer.
    Wells SA; Gosnell JE; Gagel RF; Moley J; Pfister D; Sosa JA; Skinner M; Krebs A; Vasselli J; Schlumberger M
    J Clin Oncol; 2010 Feb; 28(5):767-72. PubMed ID: 20065189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience.
    Cabanillas ME; Waguespack SG; Bronstein Y; Williams MD; Feng L; Hernandez M; Lopez A; Sherman SI; Busaidy NL
    J Clin Endocrinol Metab; 2010 Jun; 95(6):2588-95. PubMed ID: 20392874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Endocrinology].
    Missana A; Meyer P
    Rev Med Suisse; 2012 Jan; 8(323):18-22. PubMed ID: 22303734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted molecular therapies in thyroid carcinoma.
    Romagnoli S; Moretti S; Voce P; Puxeddu E
    Arq Bras Endocrinol Metabol; 2009 Dec; 53(9):1061-73. PubMed ID: 20126863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lymph node metastases and elevated postoperative calcitonin: Predictors of poor survival in medullary thyroid carcinoma.
    Siironen P; Hagström J; Mäenpää HO; Louhimo J; Arola J; Haglund C
    Acta Oncol; 2016; 55(3):357-64. PubMed ID: 26339947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer.
    Chi KN; Ellard SL; Hotte SJ; Czaykowski P; Moore M; Ruether JD; Schell AJ; Taylor S; Hansen C; Gauthier I; Walsh W; Seymour L
    Ann Oncol; 2008 Apr; 19(4):746-51. PubMed ID: 18056648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Recommendations for the management of Sorafenib in patients with hepatocellular carcinoma].
    Reig M; Matilla A; Bustamante J; Castells L; de La Mata M; Delgado M; Moreno JM; Forner A; Varela M
    Gastroenterol Hepatol; 2010 Dec; 33(10):741-52. PubMed ID: 20851505
    [No Abstract]   [Full Text] [Related]  

  • 12. Therapeutic management of metastatic medullary thyroid carcinoma: role of new tyrosine kinase inhibitors.
    García-Martín A; López-Ibarra Lozano PJ; Triviño-Ibáñez EM; Escobar-Jiménez F
    Endocrinol Nutr; 2013 Mar; 60(3):152-3. PubMed ID: 22565118
    [No Abstract]   [Full Text] [Related]  

  • 13. Long-term analysis of the efficacy and tolerability of sorafenib in advanced radio-iodine refractory differentiated thyroid carcinoma: final results of a phase II trial.
    Schneider TC; Abdulrahman RM; Corssmit EP; Morreau H; Smit JW; Kapiteijn E
    Eur J Endocrinol; 2012 Nov; 167(5):643-50. PubMed ID: 22918300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Major achievements in hepatocellular carcinoma.
    Bruix J; Llovet JM
    Lancet; 2009 Feb; 373(9664):614-6. PubMed ID: 19231618
    [No Abstract]   [Full Text] [Related]  

  • 15. Autophagic activation potentiates the antiproliferative effects of tyrosine kinase inhibitors in medullary thyroid cancer.
    Lin CI; Whang EE; Lorch JH; Ruan DT
    Surgery; 2012 Dec; 152(6):1142-9. PubMed ID: 23158184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapid response to sorafenib in metastatic medullary thyroid carcinoma.
    Frank-Raue K; Ganten M; Kreissl MC; Raue F
    Exp Clin Endocrinol Diabetes; 2011 Mar; 119(3):151-5. PubMed ID: 20827665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy.
    Kurzrock R; Atkins J; Wheler J; Fu S; Naing A; Busaidy N; Hong D; Sherman S
    Ann Oncol; 2013 Sep; 24(9):2256-61. PubMed ID: 23676418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma].
    Miller K; Bergmann L; Jäger E; Jakse G; Wirth M; Keilholz U;
    Aktuelle Urol; 2009 Jan; 40(1):27-30. PubMed ID: 19177318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thyroid carcinoma, version 2.2014.
    Tuttle RM; Haddad RI; Ball DW; Byrd D; Dickson P; Duh QY; Ehya H; Haymart M; Hoh C; Hunt JP; Iagaru A; Kandeel F; Kopp P; Lamonica DM; Lydiatt WM; McCaffrey J; Moley JF; Parks L; Raeburn CD; Ridge JA; Ringel MD; Scheri RP; Shah JP; Sherman SI; Sturgeon C; Waguespack SG; Wang TN; Wirth LJ; Hoffmann KG; Hughes M
    J Natl Compr Canc Netw; 2014 Dec; 12(12):1671-80; quiz 1680. PubMed ID: 25505208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Target therapy for hepatocellular carcinoma: is sorafenib for everybody?
    Daniele B; Di Maio M
    J Clin Gastroenterol; 2009; 43(5):389-90. PubMed ID: 19564813
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.